Title of article :
Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study
Author/Authors :
Jean-Michel Molina، نويسنده , , Jaime Andrade-Villanueva، نويسنده , , Juan Echevarria، نويسنده , , Ploenchan Chetchotisakd، نويسنده , , Jorge Corral، نويسنده , , Neal David، نويسنده , , Graeme Moyle ، نويسنده , , Marco Mancini، نويسنده , , Lisa Percival، نويسنده , , Rong Yang، نويسنده , , Alexandra Thiry، نويسنده , , Donnie McGrath ، نويسنده ,
Abstract :
Summary
Background
Atazanavir/ritonavir is as effective as lopinavir/ritonavir, with a more favourable lipid profile and less gastrointestinal toxicity, in treatment-experienced HIV-1-infected patients. We compared these two combinations directly in treat
